Literature DB >> 19204413

The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function.

Jörg Ahrens1, Reyhan Demir, Martin Leuwer, Jeanne de la Roche, Klaus Krampfl, Nilufar Foadi, Matthias Karst, Gertrud Haeseler.   

Abstract

Loss of inhibitory synaptic transmission within the dorsal horn of the spinal cord plays a key role in the development of chronic pain following inflammation or nerve injury. Inhibitory postsynaptic transmission in the adult spinal cord involves mainly glycine. Cannabidiol is a nonpsychotropic plant constituent of Cannabis sativa. As we hypothesized that non-CB receptor mechanisms of cannabidiol might contribute to its anti-inflammatory and neuroprotective effects, we investigated the interaction of cannabidiol with strychnine-sensitive alpha(1 )and alpha(1)beta glycine receptors by using the whole-cell patch clamp technique. Cannabidiol showed a positive allosteric modulating effect in a low micromolar concentration range (EC(50) values: alpha(1) = 12.3 +/- 3.8 micromol/l and alpha(1)beta = 18.1 +/- 6.2 micromol/l). Direct activation of glycine receptors was observed at higher concentrations above 100 micromol/l (EC(50) values: alpha(1) = 132.4 +/- 12.3 micromol/l and alpha(1)beta = 144.3 +/- 22.7 micromol/l). These in vitro results suggest that strychnine-sensitive glycine receptors may be a target for cannabidiol mediating some of its anti-inflammatory and neuroprotective properties. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204413     DOI: 10.1159/000201556

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  44 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids.

Authors:  Nilufar Foadi; Martin Leuwer; Reyhan Demir; Reinhard Dengler; Vanessa Buchholz; Jeanne de la Roche; Matthias Karst; Gertrud Haeseler; Jörg Ahrens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-26       Impact factor: 3.000

Review 3.  Allosteric modulation of glycine receptors.

Authors:  Gonzalo E Yevenes; Hanns Ulrich Zeilhofer
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 4.  Glycine receptors and glycine transporters: targets for novel analgesics?

Authors:  Hanns Ulrich Zeilhofer; Mario A Acuña; Jacinthe Gingras; Gonzalo E Yévenes
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

Review 5.  Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

Authors:  Henry L Blanton; Jennifer Brelsfoard; Nathan DeTurk; Kevin Pruitt; Madhusudhanan Narasimhan; Daniel J Morgan; Josée Guindon
Journal:  Drugs       Date:  2019-06       Impact factor: 9.546

Review 6.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

7.  The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice.

Authors:  Hongbo Li; Weimin Kong; Christina R Chambers; Daohai Yu; Doina Ganea; Ronald F Tuma; Sara Jane Ward
Journal:  Cell Immunol       Date:  2018-03-08       Impact factor: 4.868

8.  Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Authors:  Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

Review 9.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Authors:  Natalie E Zlebnik; Joseph F Cheer
Journal:  Annu Rev Neurosci       Date:  2016-02-24       Impact factor: 12.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.